ARMP Earnings Date & History
Armata Pharmaceuticals Inc (NYSE MKT LLC) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 4:07 PM ET
Armata Pharmaceuticals Inc
Biotechnology
- Next earnings date
- Tuesday, November 10, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.40
- Revenue estimate
- $459,000
ARMP earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, May 13, 2026 | Q1 2026 | $-0.39 | $-3.16 | -715.3% | $789,000 |
| Wednesday, March 25, 2026 | Q4 2025 | $-0.29 | $-3.27 | -1045.0% | $1.1M |
| Wednesday, November 12, 2025 | Q3 2025 | $-0.43 | $-0.74 | -72.7% | $1.2M |
| Tuesday, August 12, 2025 | Q2 2025 | $-0.40 | $-0.45 | -13.1% | $2.2M |
What the market is watching in ARMP's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next ARMP earnings date?
- Armata Pharmaceuticals Inc is scheduled to report on Tuesday, November 10, 2026 (Time TBD). Dates can change until the company confirms them.
- Does ARMP report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for ARMP?
- Consensus EPS for the upcoming quarter is $-0.40, on revenue of $459,000.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
ARMP earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.